DLV Vision is excited to announce that we are now offering your patients the Alcon AcrySof PanOptix and PanOptix Toric trifocal intraocular lens (IOL) implants, which were approved by the FDA on August 27, 2019. The PanOptix IOL’s have already been in use for over four years in more than 70 countries. DLV Vision will continue to utilize Softec HD with blended monovision as our primary recommendation for those patients who want both distance and near vision. PanOptix will be recommended as a secondary line of treatment for patients who cannot or will not tolerate monovision.
The PanOptix treats a broad range of spherical refractive error, and the PanOptix Toric can treat from 1.5 to 3.75 D of astigmatism on the spectacle plane.
The indications and candidate selection for AcrySof PanOptix and PanOptix Toric trifocal intraocular lens are as follows:
- Intolerant of monovision
- Patients with cataracts or are a candidate for a clear lens extraction
- Patients who want near and intermediate vision without compromising distance vision (except night vision).
Potential side effects are similar to that of a normal multifocal intraocular lens and include but are not limited to:
- Halo and/or glare at night or in low light conditions
- Risk of mild loss of contrast
Please note, a full pre-operative evaluation is required. DLV Vision is thrilled that we will have this new lens option available to your patients. Thank you again for all your support and join us in celebrating this exciting new technology now available in the United States!
Paul J Dougherty, MD
The comments are closed.